source
- Roivant's brepocitinib cuts steroid use in non-infectious uveitis in Phase 3 trialsRoivant Sciences and its subsidiary Priovant reported that their TYK2/JAK inhibitor brepocitinib met all primary and secondary endpoints in two identical Phase 3 studies (Clarity‑1 and Clarity‑2) i…
- FDA issues final guidance on drug-related mobile applicationsThe FDA has released its final guidance addressing software applications that are used in connection with prescription drugs. The guidance clarifies how the agency will evaluate and regulate apps…